Biodegradable intrascleral implant of triamcinolone acetonide in experimental uveitis

Journal of Ocular Pharmacology and Therapeutics

Volumn 25, Issue 3, 2009, Pages 201-207

  Shin, Jae Pil ^a   Park, Yong Chul ^a   Oh, Ji Hae ^a   Lee, Ji Woong ^a   Kim, Yu Mi ^b   Lim, Jeong Ok ^a   Kim, Si Yeol ^a  

^a Kyungpook National University School of Medicine   (South Korea)

^b Kyungpook National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

POLYLACTIDE; TRIAMCINOLONE ACETONIDE; TUBERCULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; AQUEOUS HUMOR; ARTICLE; BIODEGRADABLE IMPLANT; CELL COUNT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; ELECTRORETINOGRAPHY; EYE INFLAMMATION; HISTOPATHOLOGY; NONHUMAN; OPTIC DISK; QUANTITATIVE ANALYSIS; RABBIT; TREATMENT OUTCOME; UVEITIS; VITREOUS OPACITY;

ABSORBABLE IMPLANTS; ANIMALS; CELL COUNT; CHRONIC DISEASE; DRUG ADMINISTRATION ROUTES; DRUG CARRIERS; DRUG COMPOUNDING; DRUG IMPLANTS; ELECTRORETINOGRAPHY; GLUCOCORTICOIDS; POLYESTERS; RABBITS; SCLERA; TRIAMCINOLONE ACETONIDE; TUBERCULIN; UVEITIS; VITREOUS BODY;

EID: 66249146889     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2008.0086     Document Type: Article

References (40)

1. Smith, J.R. Management of uveitis. Clin. Exp. Med. 4:21-29, 2004.
2. Gaudio, P.A. A review of evidence guiding the use of corticosteroids in the treatment of intraocular inf ammation. Ocul. Immunol. Inflamm. 12:169-192, 2004.
3. Dunn, J.P. Review of immunosuppressive drug therapy in uveitis. Curr. Opin. Ophthalmol. 15:293-298, 2004.
4. Helm, C.J., and Holland, G.N. The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am. J. Ophthalmol. 120:55-64, 1995.
5. Tanner, V., Kanski, J.J., and Frith, P.A. Posterior sub-Tenon's triamcinolone injections in the treatment of uveitis. Eye. 12:679-685, 1998.
6. Young, S., Larkin, G., Branley, M., et al. Safety and eff cacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin. Experiment. Ophthalmol. 29:2-6, 2001.
7. Martidis, A., Duker, J.S., Greenberg, P.B., et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 109:920-927, 2002.
8. Zhou, T., Lewis, H., Foster, R.E., et al. Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy. J. Control Release. 55:281-295, 1998.
9. Gillies, M.C., Simpson, J.M., Luo, W., et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch. Ophthalmol. 121:667-673, 2003.
10. Nozik, R.A. Periocular injection of steroids. Trans. Am. Acad. Ophthalmol. Otolaryngol. 76:695-705, 1972.
11. Riordan-Eva, P., and Lightman, S. Orbital floor steroid injections in the treatment of uveitis. Eye. 8:66-69, 1994.
12. Modarres, M., Parvaresh, M.M., and Peyman, G.A. Accidental subretinal injection of triamcinolone acetonide. Ophthalmic. Surg. Lasers. 29:935-938, 1998.
13. Smith, J.R., George, R.K., and Rosenbaum, J.T. Lower eyelid herniation of orbital fat may complicate periocular corticosteroid injection. Am. J. Ophthalmol. 133:845-847, 2002.
14. Moshfeghi, D.M., Lowder, C.Y., Roth, D.B., et al. Retinal and choroidal vascular occlusion after posterior sub-tenon triamcinolone injection. Am. J. Ophthalmol. 134:132-134, 2002.
15. Degenring, R.F., and Jonas, J.B. Intravitreal injection of triamcinolone acetonide as treatment for chronic uveitis. Br. J. Ophthalmol. 87:361, 2003.
16. Antcliff, R.J., Spalton, D.J., Stanford, M.R., et al. Intravitreal triamcinolone for uveitic cystoid macular edema: An optical coherence tomography study. Ophthalmology. 108: 765-772, 2001.
17. Jaffe, G.J., Pearson, P.A., and Ashton, P. Dexamethasone sustained drug delivery implant for the treatment of severe uveitis. Retina. 20:402-403, 2000.
18. Jaffe, G.J, Ben-nun, J., Guo, H., et al. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 107:2024-2033, 2000.
19. Ozkiris, A., and Erkilic, K. Complications of intravitreal injection of triamcinolone acetonide. Can. J. Ophthalmol. 40:63-68, 2005.
20. Duker, J.S., Robinson, M., Anand, R., et al. Initial experience with an eight-month sustained-release intravitreal ganciclovir implant for the treatment of CMV retinitis associated with AIDS. Ophthalmic. Surg. Lasers. 26:442-448, 1995.
21. Olsen, T.W., Aaberg, S.Y., Geroski, D.H., et al. Human sclera: thickness and surface area. Am. J. Ophthalmol. 125:237-241, 1998.
22. Ambati, J., and Adamis, A.P. Transscleral drug delivery to the retina and choroid. Prog. Retin. Eye. Res. 21:145-151, 2002.
23. Kim, Y.M., Lim, J.O., Kim, H.G., et al. A novel design of one side coated biodegradable intrascleral implant for the sustained release of triamcinolone acetonide. Eur. J. Pharm. Biopharm. 70:179-186, 2008.
24. Jaffe, G.J., Yang, C.S., Wang, X.C., et al. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology. 105:46 -56, 1998.
25. Hogan, M.J., Kimura, S.J., and Thygeson, P. Signs and symptoms of uveitis: I: Anterior uveitis. Am. J. Ophthalmol. 47:155-170, 1959.
26. Nussenblatt, R.B., Palestine, A.G., Chan, C.C., et al. Standardization of vitreal inf ammatory activity in intermediate and posterior uveitis. Ophthalmology. 92:467-471, 1985.
27. Inoue, M., Takeda, K., Morita, K., et al. Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am. J. Ophthalmol. 138:1046-1048, 2004.
28. Thomas, E.R., Wang, J., Ege, E., et al. Intravitreal triamcinolone acetonide concentration after subtenon injection. Am. J. Ophthalmol. 142:860-861, 2006.
29. Park, Y.W., Lim, J.H., Shin, J.P., et al. Ocular concentration after subtenon and intravitreal injection of triamcinolone acetonide in rabbits. J. Korean. Ophthalmol. Soc. 49:333-339, 2008.
30. Wilson, C.A., Berkowitz, B.A., Sato, Y., et al. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch. Ophthalmol. 110:1155-1159, 1992.
31. Mizuno, S., Nishiwaki, A., Morita, H., et al. Effects of periocular administration of triamcinolone acetonide on leukocyte-endothelium interactions in the ischemic retina. Invest. Ophthalmol. Vis. Sci. 48:2831-2836, 2007.
32. Bolliger, G.A., Kupferman, A., and Leibowitz, H.M. Quantitation of anterior chamber inf ammation and its response to therapy. Arch. Ophthalmol. 98:1110 -1114, 1980.
33. Jaffe, G.J., Yang, C.H., Guo, H., et al. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest. Ophthalmol. Vis. Sci. 41:3569-3575, 2000.
34. Knepper, P.A., Breen, M., Weinstein, H.G., et al. Intraocular pressure and glycosaminoglycan distribution in the rabbit eye: effect of age and dexamethasone. Exp. Eye. Res. 27:567-575, 1978.
35. Cheng, C.K., Berger, A.S., Pearson, P.A., et al. Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis. Invest. Ophthalmol. Vis. Sci. 36:442-453, 1995.
36. Felt-Baeyens, O., Eperon, S., Mora, P., et al. Biodegradable scleral implants as new triamcinolone acetonide delivery systems. Int. J. Pharm. 322:6-12, 2006.
37. Okabe, K., Kimura, H., Okabe, J., et al. Intraocular tissue distribution of betamethasone after intrascleral administration using a non-biodegradable sustained drug delivery device. Invest. Ophthalmol. Vis. Sci. 44:2702-2707, 2003.
38. Okabe, J., Kimura, H., Kunou, N., et al. Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate. Invest. Ophthalmol. Vis. Sci. 44:740-744, 2003.
39. Yang, C.S., Khawly, J.A., Hainsworth, D.P., et al. An intravitreal sustained-release triamcinolone and 5-f uorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch. Ophthalmol. 116:69-77, 1998.
40. Mruthyunjaya, P., Khalatbari, D., Yang, P., et al. Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis. Arch. Ophthalmol. 124:1012-1018, 2006.